BECAUSE EYESIGHT MATTERS
Blindness and severe vision impairment consecutive to eye diseases affects more than 200 million people worldwide. Indeed, current diagnosis come up too late and treatment is not optimal for many diseases. The reason is the difficulty of assessing the disease state and the treatment effect due to the limitations of the standard imaging instruments. At EarlySight, we invented a cellular-level imaging modality with unprecedented contrast to detect minor structural changes of the retina in only few seconds. Thanks to transscleral illumination, we are able to monitor day-to-day effects of treatment in a quick and non-invasive manner.
OBSERVE THE CELLULAR STRUCTURE
Automatic segmentation and quantification of the retinal pigment epithelium layer. Understand and visualize the origins of many diseases such as age-related macular degeneration. Measure the cell density or size and use quantitative metrics as bio-markers and therapeutic endpoints.
UP TO THE SMALLEST CAPILLARIES
Observe the vascular layer with details never seen before. The micro-vasculature structure and the small capillaries being micron-thick are visible with EarlySight technology. And even if no blood flow is present. Making it the ideal instrument to visualize micro-aneurysms.
THEY SUPPORT US
